

26 OCT 1987

No. U.10/27/3

NORTH WESTERN REGIONAL HEALTH AUTHORITY:

CHAIRMAN TO CONSIDER:

AUTHORISATION OF URGENT
ACTION PENDING A REPORT
TO THE REGIONAL HEALTH
AUTHORITY

To	Noted
R.A.	
R.M.O.	
R.N.O.	
R.T.	
R.W.O.	
Management Secretariat	

Subject: Purchase of Factor VIII

Date: 23rd October, 1987.

Originator: Dr. H.M. Gunson

- Factor VIII concentrate for the treatment of haemophilia patients has been obtained from 2 sources:-
 - Blood Products Laboratory in Elstree, where plasma sent from the Regional Transfusion Service is fractionated and the products returned pro rata to the Region.
 - Purchases from commercial sources for which ad hoc grants have been made on an annual basis.
- In February 1987, the General Management Group approved an additional allocation of £117,000 for the purchase of Factor VIII during 1987/88. However, the usage of Factor VIII in the Region has increased further due to the need to administer additional quantities to haemophilia patients suffering from AIDS-related diseases and the performance of essential surgical procedures.
- It is anticipated that up to a further million units of Factor VIII will need to be purchased to satisfy therapeutic demand to the end of March 1988.
- Sources of supply and price are summarised below:-
 - Purchase of additional Factor VIII from the existing contract with Cutter Laboratories at 13.5p per unit, for which additional funding of £135,000 ^{would} be required.
 - Virement from a projected underspend on blood packs to enable the purchase of Factor VIII from Travenol without the need for additional funds as follows:-

Haemophil	@ 12.5p per unit	400,000 units	£ 50,000
Monoclonal Factor <u>VIII</u>	@ 25.0p per unit	275,000 units	£ 68,750
"	free	75,000 units	-

(Optional) Haemophil	Seen by Chief Officer:	
@ 12.0p per unit	250,000 units	£ 30,000
		<u>£148,750</u>

Date considered: - 3 NOV 1987

Terms of approval:

* **APPROVED** *

GRO-C

* REFERENCE TO THIS MATTER
TO BE INCLUDED AS PART
OF THE NEXT QUARTERLY REPORT
OF THE AGM (P).

S 101

SEE ATTACHED MEMO 4/11/87).

NORTH WESTERN REGIONAL HEALTH AUTHORITY:CHAIRMAN TO CONSIDER.AUTHORISATION OF URGENT ACTION PENDING A REPORT
TO THE REGIONAL HEALTH AUTHORITY

Travenol have agreed that blood packs not used but already paid for on an annual contract may be used as a credit for the purchase of Factor VIII. It is anticipated that as the usage of blood packs has not been at the rate expected due to the difficulty the Service has experienced in blood collection, together with a policy of running down stocks to a minimum level, sufficient credit will be available to purchase Factor VIII as outlined at b) above.

5. Senior Supplies Officers and Managers within the BTS have been involved in agreeing this transaction with Travenol, which will remain available for 2 weeks from the date of this report.
6. It is recommended that the Chairman agree a virement from the blood pack budget to the purchase of Factor VIII to the amounts indicated.